Posts Tagged
‘ONTY’
by Phil - March 27th, 2010 2:27 pm
Wheeee – the S&P is up 6 points this week!

I know, I can hardly contain my own excitement either. It almost makes my cash-out decision of the 19th (where we did open at 1,166) seem silly what with us missing a 6-point (0.5%) rally this week and all.. Of course, you have to look at the bigger picture like the year-to-date, which has us up a whopping 34 points since January 4th although, to be fair, 18 of those 34 points were gained by Jan 19th, then we had that sell-off thing and THEN we had a nice rally, all the way back to 16 points over the Jan 19th high. See, I’m not early with my top call – I’m 2 months late! We could have taken a vacation from Jan 19th to today and missed very little upside action.
We don’t cash out just because we’re at a top. Hell, we love playing tops, bottoms, middles – whatever… We cash out when it’s no fun to play and, as many, many members commented this week – it’s much less fun to play when the market turns toppy and churny like it is now. My cash out call was for a Market Mental Health Break ahead of earnings season and we did have a very nice, relaxing week just hanging out in Member Chat and, yes, making the occasional play but it’s more like when you go to the track and toss a couple of bucks on a race to keep it interesting – and that makes it fun!
We passed the Health Care Bill on Sunday and, instead of ending the Universe as promised by Republicans and Tea Party enthusiasts alike, it actually sparked a huge dollar rally that gave us a full 2.5% run for the week, closing at a year high of 81.60. We were thrilled as we had taken gold shorts and SCO (ultra-short oil) longs the week before, when oil was testing $83 a barrel – now back at $80 on the nose to close out this week.
Seven banks were shut down by the FDIC last weekend (and 4 more bit the dust last night), Greece was still up in the air, TIF missed earnings and the Four Seasons in Maui missed a mortgage payment but the thing that made me gladdest we were on the sidelines was…

Tags: AMZN, BIDU, C, CHK, DIA, EWJ, FCX, GLD, Oil, ONTY, QID, SMN, SPWRA, TNA, TZA, UGL, USO
Posted in Immediately available to public | Join Member's Chat - 46 Comments Here »
Email This Post
Facebook
Twitter
LinkedIn
del.icio.us
Digg
by Phil - August 29th, 2009 8:28 am
It has been a crazy few weeks!
I went back over our Long Shots list from August 9th, thinking all our picks must be doing great but really only C, with a 67% gain, is really outperforming. Long spreads on UYG and BHI are on target for nice gains but haven’t moved much. Looking at our original picks in Pharmboys Phavorites from the same week, GSK is on track and up nicely already, our AZN cover is up 45% and MRK flew up 19% already. On the riskier Biotech side, ARIA’s stock is up 16% and our spreads are all performing well, ONTY has been flat, OGXI is up 33% and the Jan $17.50s are up a rockin’ 63% with that "cautious" spread up a surprising 75% already.
SPPI had a wild ride (as we predicted with TSCM’s failed assassination attempt) and the buy/write is already up 24%, the Feb vertical is up 50% and the naked Jan put sale is up 27% and our Feb hedge play is right on track so all good there and a fine example of how following Cramer and his lackeys and and doing the opposite of what they say can be very profitable! Congrats to Pharmboy for a very fine set of picks, proving once again that there is room for research and fundamentals - not a single loser in the bunch in a choppy market! It was very timely as I had mentioned just that week in my interview with AOL Finance that XLV was my favorite sector and our IHI pick of 8/10 is up 28% on the naked Feb $45 put sale while the Feb $45 calls have already jumped 16%. It was a great call as IHI outperformed XLV and all our major indexes.
So our energy service pick (BHI) and overall financial pick (UYG) have not done much in 3 weeks and those were our leading sectors into my call to cash out our exposed long calls on Aug 13th, ahead of expirations. The Dow was at 9,400 on that day and now, a bit more than 2 weeks later, we’ve gained another 144 points but to listen to the MSM, you would think you are missing the rally of the century the past couple of weeks. This is one of the reasons I’ve gotten a bit more cynical about the rally – there is so much hype and so…

Tags: AAPL, AIG, ARIA, BHI, C, DIA, DRYS, DXD, EDZ, ELN, EP, ERY, FNM, FRE, FXP, GENZ, GNK, GOOG, GS, GSK, IHI, JNJ, MRK, NVS, OGXI, OIH, ONTY, PALM, PARD, SNY, SPPI, SRS, TOL, TSCM, UYG, XLV
Posted in Immediately available to public | Join Member's Chat - 49 Comments Here »
Email This Post
Facebook
Twitter
LinkedIn
del.icio.us
Digg
by Phil - August 8th, 2009 3:02 pm
Greetings PSW members from Pharmboy!
This is my first shot at writing a formal post for everyone on a few biotech/pharma picks that I believe have promise for nice returns over the next 6 to 18 months. Much of the work here is a compilation of readings elsewhere, summarized for you all to make your own conclusions. Here we go:
Big Pharma
GlaxoSmithKline (GSK) – has a robust pipeline in inflammation, cancer and other therapeutic areas. A few line extensions could do well generic simvistatin (Zocor) + Avandia) for cardio/diabetes. Will compete against Vytorin, and others like it. In the pipeline, GSK has an Orexin antagonist for sleep disorders (very hot area), several drugs for asthma/COPD in Phase II including a PDE-4 and FLAP inhibitor. The asthma/COPD drugs have huge potential as a monotherapy or in some combination, as they are the newest line of therapies that have come along for asthma/COPD in some time (GSKs strength). GSK also has a VLA4 antagonist for multiple sclerosis in phase II.
This is the first I have seen of this in a pipeline for clinical trials. VLA4 is the target of Tysabri from BIIB. One hypothesis is that a small molecule that binds to the receptor but does not completely knock out the receptor like a mAb may be better for MS patients. Remember, Tysabri has a potential of a rare neurological condition progressive multifocal leukoencephalopathy (PML) when administered in combination with interferon beta-1a, another immunosuppressive drug often used in the treatment of multiple sclerosis.
One other note for growth, Amgen (AMGN) revealed its commercialization strategy for osteoporosis treatment, denosumab, one of the most keenly anticipated new drugs set to reach the market for several years, naming GlaxoSmithKline (GSK) as partner in Europe and other countries. GSK has several cancer treatments as well as vaccines in various stages, so it is my belief that their pipeline is rich and diverse. Current yield is 4.8%.
Phi’s Take: 4.8% and Pharm likes the pipeline –
…

Tags: AMGN, ARIA, AZN, GSK, MRK, OGXI, ONTY, SPPI
Posted in Virtual Portfolio Review | Join Member's Chat - 23 Comments Here »
Email This Post
Facebook
Twitter
LinkedIn
del.icio.us
Digg
February 11th, 2012 11:02 am
Courtesy of ZeroHedge. View original post here.
Submitted by Tyler Durden.
Some of our German readers may be laboring under the impression that following the €110 billion first Greek bailout agreed upon and executed in May 2010, the second Greek bailout would cost a "mere" €130 billion. Alas we have new for you - as of this morning, the formal cost of rescuing Greece for the adjusted adjusted adjusted second time has just risen to €145 billion, €175 billion, a whopping €210 billion, bringing the total explicit cost of all Greek bailout funds to date (and many more in sto...
more from Tyler
February 11th, 2012 10:35 am
Courtesy of Doug Short.
The $OEXA200R (the percentage of S&P 100 stocks above their 200 DMA) is a technical indicator available on StockCharts.com that can be used to forecast conservative entry and exit points for the stock market.
The OEXA is used to find the "sweet spot" time period in the market when you have the best chance of making money. See Is This the Best Stock Market Indicator Ever? for a discussion of this technical tool.
The chart below is current through the February 3rd close.
After a major S&P correction, the conditions for safe re-entry into the market are when:
 
a) $OEXA200R rises above 65%. And two of the following three...
more from Chart School
February 11th, 2012 3:28 am
Violent Protests in Greece; 6 Cabinet Members Resign; LAOS leader "I Would Rather Starve Than be Under German Jackboot"; Controversy Over Missing Paragraphs
Courtesy of Mish
Imagine you are asked to sign a document but three pages were missing. Further imagine the documents you were asked to sign were written in English but you only speak Greek. Would you sign?
That is exactly the predicament Greek officials were placed in by the Troika. Here is the story sent to me by Demetri Kofinas at Capital Account.
Hello Mish
George Karatzaferis leader of LOAS political party gave a speech today addressing why he refused to sign this latest agreement. In his speech, he said that he a...
more from Ilene
February 11th, 2012 12:00 am
Top 5 RisersStockRatingAnalysis
ICABUYThe projected value for Empresas ICA is still rising quickly even though past earnings have already improved significantly.
XBUYThe projected value for US Steel is still rising quickly even though past earnings have already improved significantly.
FEICBUYProjected value continues to rise for FEI while long term increases in earnings growth are also becoming more widely expected.
ASBCBUYMany analysts are expecting higher than previously expected long term growth from Associated Bancorp, and its near-term earnings outlook is also improving....
more from Sabrient
February 10th, 2012 6:20 pm
Courtesy of Benzinga.
The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday February 10, 2012:
Actuant Acquires Jeyco Pty
The Deal:
Actuant (NYSE: ATU) announced Friday that it has acquired Jeyco Pty Ltd (“Jeyco”). Headquartered near Perth, Australia, Jeyco designs and provides specialized mooring, rigging and towing systems and services to the offshore oil & gas industry in Australia and other international markets. Additionally, its highly engineered products are used in a variety of applications for other markets including cyclone mooring and marine, defense and mining tow systems. Jeyco generates annual revenues of approximately $20 million.
Actuant shares closed at $27.33 Friday, a loss of 0.18% on average volume.
...
http://www.insidercow.com/ more from Insider
February 10th, 2012 4:14 pm
Submitted by Mark Hanna
Courtesy of MarketMontage. View original post here.
A little flurry of buying in the closing 5 minutes tacked on 2 S&P points and took the major indexes off the lows. Only the Russell 2000 finished with a greater than 1% loss (1.4%) as it has been relatively weak versus the senior indexes for the past few sessions. While today was the "worst day of the year" – it was quite a low bar as the previous biggest loss on the S&P 500 was -0.57%.
The S&P 500 held well above the 10 day moving average (didn't even really touch it) and did not even attempt to fill the gap from last Friday's employment report. The teflon market rolls on for now. Specul...
more from Mark
February 10th, 2012 4:11 pm
Courtesy of John Nyaradi.
Greece was “saved” for less than 24 hours but now major ETFs around the world skid into the weekend on Greek fears
After wangling for a week or more, Greek took their new deal to the European Ministers meeting, only to have it promptly rejected and so as we go into the weekend, major global markets and ETFs have again hit the skids on Greece.
After two years of wangling, the European zone is demanding yet more and deeper cuts for Greece to qualify for the next round of bailout loans that will keep the country from going bankrupt on March 20th.
Major European and United States ETF responded negatively to the new developments:
SPDR Dow Jones Industrial ETF (NYSEARCA:...
more from John
February 10th, 2012 1:40 pm
Reminder: David is available to chat with Members, comments are found below each post.
Click here for the full report.
To learn more, sign up for David's
free newsletter and receive the
free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. -
Ilene...
more from David
February 10th, 2012 1:22 pm
Today’s tickers: TRLG, KR & IGT
...
more from Caitlin
February 6th, 2012 9:02 am
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
Optrader
...
more from OpTrader
February 5th, 2012 5:19 am
NEW: Elliott and Ilene are available to chat with Members regarding topics presented in SWW, comments are found below each post.
Here's the latest Stock World Weekly, called "The Relentless Pursuit of Meaningless Metrics."
...
more from SWW
January 30th, 2012 7:22 am
Here is a quick update of past trades and our current position.
AA Money
No trade this week as we wait for AA to settle. Phil remarked last week that AA seemed overvalued. In the meantime, it looks like we might have to roll our Feb 9 calls. Good thing we sold only 5 of them against our position.
Last week P&L - 310.00
We lost ground last week, but we still have 11 months to sell premium!
FAS Money
Very good week for FAS Money as we benefited from the large amount of premium sold the previous week. We covered most of the shorts in advance of the Fed speech, but sold another set of options on Wednesday after the speech - 2 FAS calls that expired worthless on Friday, 2 FAS put that we are still holding and 2 FAZ put that we bought back for a profit on Friday. A late stick comparable to last week's almost gave us problems at the end of the day though!
Last week P&L - $4277.00
IWM Money
A decent week in this virtual portfo...
more from Strategies
January 18th, 2012 1:09 am
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Finding new and exciting Biotech companies that target novel mechanisms is like trying to find a needle in a haystack. Sure there are many companies working on cutting edge science, but investing in those companies to reap the rewards of their work is a very dangerous game. More often than not, companies fail because the mechanism does not pan out, the compound(s) do not have pharmacokinetics (get into the body or last very long in the body), or an adverse event happens that knocks years off a development timeline. In addition, the stock can be manipulated by market makers so investors don't know which way is up. I approach investing in biotechs as a long term prospect. I continue to like our current portfolio of biotech companies (join in chat for many of those plays), and we continually add/subtract shares and sell/buy options on ...
more from Pharmboy
About Phil:
Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...
Learn more About Phil >>
About Ilene:
Ilene is editor and affiliate program
coordinator for PSW. She manages the Favorites backup site
(blogroll, archives,
more).
Contact Ilene to learn about our affiliate and
content sharing
programs.
Favorites Site >>